{"entity":{"type":"insider","cik":"0001532635","url":"/insider/0001532635","json_url":"/insider/0001532635.json","name":"Aisling Capital Partners III LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":22,"n_filings":20,"first":"2011-10-25","last":"2018-07-12","span_basis":"filed_date"},"name_variants":[{"name":"Aisling Capital Partners III LLC","source":"filing","n_filings":20,"first_seen":"2011-10-25","last_seen":"2018-07-12"}],"transactions":[{"id":6282955,"accession":"0000899243-18-019810","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-019810","line_url":"/filing/0000899243-18-019810#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LP; ELMS STEVE; Aisling Capital Partners III LLC; SCHIFF ANDREW N","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1400000.0,"shares_display":"1,400,000","price_per_share":179.43,"price_display":"179.43","price_state":"stated","total_value":251202000.0,"total_display":"251,202,000.00","total_whole":"251,202,000","shares_owned_after":2038920.0,"shares_owned_after_display":"2,038,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-07-10","filed_date":"2018-07-12","scope":"insider"},{"id":5159611,"accession":"0000950142-17-002235","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-17-002235","line_url":"/filing/0000950142-17-002235#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL III LP; ELMS STEVE; Aisling Capital Partners III LLC; SCHIFF ANDREW N; Purcell Dennis J; Aisling Capital Partners III LP","owner_display_name":"AISLING CAPITAL III LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250000.0,"shares_display":"250,000","price_per_share":80.5,"price_display":"80.50","price_state":"stated","total_value":20125000.0,"total_display":"20,125,000.00","total_whole":"20,125,000","shares_owned_after":3438920.0,"shares_owned_after_display":"3,438,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-19","filed_date":"2017-12-20","scope":"insider"},{"id":4735884,"accession":"0000950142-17-002107","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-17-002107","line_url":"/filing/0000950142-17-002107#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LLC; AISLING CAPITAL III LP; Purcell Dennis J; SCHIFF ANDREW N; Aisling Capital Partners III LP; ELMS STEVE","owner_display_name":"Aisling Capital Partners III LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":75.0,"price_display":"75.00","price_state":"stated","total_value":37500000.0,"total_display":"37,500,000.00","total_whole":"37,500,000","shares_owned_after":3688920.0,"shares_owned_after_display":"3,688,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-22","filed_date":"2017-11-27","scope":"insider"},{"id":5312278,"accession":"0000950142-17-000108","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-17-000108","line_url":"/filing/0000950142-17-000108#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"ELMS STEVE; Aisling Capital Partners III LP; AISLING CAPITAL III LP; Purcell Dennis J; SCHIFF ANDREW N; Aisling Capital Partners III LLC","owner_display_name":"ELMS STEVE","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":160000.0,"shares_display":"160,000","price_per_share":31.0,"price_display":"31.00","price_state":"stated","total_value":4960000.0,"total_display":"4,960,000.00","total_whole":"4,960,000","shares_owned_after":4188920.0,"shares_owned_after_display":"4,188,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-10","filed_date":"2017-01-12","scope":"insider"},{"id":2545318,"accession":"0000950142-16-004060","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950142-16-004060","line_url":"/filing/0000950142-16-004060#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LP","owner_display_name":"Aisling Capital Partners III LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":908565.0,"shares_owned_after_display":"908,565","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-06","filed_date":"2016-07-06","scope":"insider"},{"id":3241927,"accession":"0000950142-16-003763","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-16-003763","line_url":"/filing/0000950142-16-003763#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL III LP; Aisling Capital Partners III LLC; Purcell Dennis J; ELMS STEVE; Aisling Capital Partners III LP; SCHIFF ANDREW N","owner_display_name":"AISLING CAPITAL III LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":232558.0,"shares_display":"232,558","price_per_share":21.5,"price_display":"21.50","price_state":"stated","total_value":4999997.0,"total_display":"4,999,997.00","total_whole":"4,999,997","shares_owned_after":4028920.0,"shares_owned_after_display":"4,028,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-17","filed_date":"2016-05-19","scope":"insider"},{"id":8897993,"accession":"0000950142-15-002621","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-002621","line_url":"/filing/0000950142-15-002621#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Aisling Capital Partners III LLC; Aisling Capital Partners III LP; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":27.5,"price_display":"27.50","price_state":"stated","total_value":5500.0,"total_display":"5,500.00","total_whole":"5,500","shares_owned_after":3796362.0,"shares_owned_after_display":"3,796,362","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-11","filed_date":"2015-12-15","scope":"insider"},{"id":8897991,"accession":"0000950142-15-002576","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-002576","line_url":"/filing/0000950142-15-002576#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"T2 Biosystems, Inc.","issuer_ticker":"TTOO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL III LP; Aisling Capital Partners III LP; Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; Purcell Dennis J","owner_display_name":"AISLING CAPITAL III LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":307692.0,"shares_display":"307,692","price_per_share":9.75,"price_display":"9.75","price_state":"stated","total_value":2999997.0,"total_display":"2,999,997.00","total_whole":"2,999,997","shares_owned_after":2830992.0,"shares_owned_after_display":"2,830,992","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-12-09","filed_date":"2015-12-09","scope":"insider"},{"id":8707781,"accession":"0000950142-15-002461","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-002461","line_url":"/filing/0000950142-15-002461#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; AISLING CAPITAL III LP; SCHIFF ANDREW N; Aisling Capital Partners III LP; ELMS STEVE","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":265000.0,"shares_display":"265,000","price_per_share":26.5,"price_display":"26.50","price_state":"stated","total_value":7022500.0,"total_display":"7,022,500.00","total_whole":"7,022,500","shares_owned_after":3796182.0,"shares_owned_after_display":"3,796,182","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-17","filed_date":"2015-11-19","scope":"insider"},{"id":8131979,"accession":"0000950142-15-002434","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950142-15-002434","line_url":"/filing/0000950142-15-002434#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LLC; ELMS STEVE; Aisling Capital Partners III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1955.0,"shares_display":"1,955","price_per_share":27.4702,"price_display":"27.47","price_state":"stated","total_value":53704.241,"total_display":"53,704.24","total_whole":"53,704","shares_owned_after":3531182.0,"shares_owned_after_display":"3,531,182","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-13","filed_date":"2015-11-16","scope":"insider"},{"id":8131974,"accession":"0000950142-15-002434","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-002434","line_url":"/filing/0000950142-15-002434#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LLC; ELMS STEVE; Aisling Capital Partners III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":76714.0,"shares_display":"76,714","price_per_share":27.6523,"price_display":"27.65","price_state":"stated","total_value":2121318.5422,"total_display":"2,121,318.54","total_whole":"2,121,319","shares_owned_after":3529207.0,"shares_owned_after_display":"3,529,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-12","filed_date":"2015-11-16","scope":"insider"},{"id":8779181,"accession":"0000950142-15-000194","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-000194","line_url":"/filing/0000950142-15-000194#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Versartis, Inc.","issuer_ticker":"VSAR","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; AISLING CAPITAL III LP; Aisling Capital Partners III LP; ELMS STEVE; SCHIFF ANDREW N","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":145000.0,"shares_display":"145,000","price_per_share":17.25,"price_display":"17.25","price_state":"stated","total_value":2501250.0,"total_display":"2,501,250.00","total_whole":"2,501,250","shares_owned_after":2139568.0,"shares_owned_after_display":"2,139,568","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-01-27","filed_date":"2015-01-29","scope":"insider"},{"id":8354994,"accession":"0000950142-15-000157","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-000157","line_url":"/filing/0000950142-15-000157#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"AGILE THERAPEUTICS INC","issuer_ticker":"AGRX","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LP; Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP","owner_display_name":"Aisling Capital Partners III LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":811966.0,"shares_display":"811,966","price_per_share":5.85,"price_display":"5.85","price_state":"stated","total_value":4750001.1,"total_display":"4,750,001.10","total_whole":"4,750,001","shares_owned_after":2983797.0,"shares_owned_after_display":"2,983,797","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-01-23","filed_date":"2015-01-27","scope":"insider"},{"id":6276981,"accession":"0001104659-14-061090","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-14-061090","line_url":"/filing/0001104659-14-061090#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"T2 Biosystems, Inc.","issuer_ticker":"TTOO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LP; ELMS STEVE; SCHIFF ANDREW N; Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LLC","owner_display_name":"Aisling Capital Partners III LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":454545.0,"shares_display":"454,545","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":2523300.0,"shares_owned_after_display":"2,523,300","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-12","filed_date":"2014-08-14","scope":"insider"},{"id":6487134,"accession":"0001140361-14-031039","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-031039","line_url":"/filing/0001140361-14-031039#line-2","is_derivative":false,"issuer_cik":"0001120478","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001120478","owner_cik":null,"owner_name":"Aisling Capital Partners III LLC; Purcell Dennis J; SCHIFF ANDREW N; AISLING CAPITAL III LP; Aisling Capital Partners III LP; ELMS STEVE; GOLDSTEIN DOV A MD","owner_display_name":"Aisling Capital Partners III LLC","owner_url":null,"role":"Director, Officer (CFO and Treasurer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":"CFO and Treasurer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":413077.0,"shares_display":"413,077","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":5370001.0,"total_display":"5,370,001.00","total_whole":"5,370,001","shares_owned_after":3452493.0,"shares_owned_after_display":"3,452,493","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-06","filed_date":"2014-08-06","scope":"insider"},{"id":6990228,"accession":"0000950142-14-000941","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-14-000941","line_url":"/filing/0000950142-14-000941#line-1","is_derivative":false,"issuer_cik":"0000876378","issuer_name":"TRANSENTERIX INC.","issuer_ticker":"TRXC","issuer_name_source":null,"issuer_url":"/issuer/0000876378","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; AISLING CAPITAL III LP; Aisling Capital Partners III LP","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1037767.0,"shares_display":"1,037,767","price_per_share":4.0,"price_display":"4.00","price_state":"stated","total_value":4151068.0,"total_display":"4,151,068.00","total_whole":"4,151,068","shares_owned_after":8335819.0,"shares_owned_after_display":"8,335,819","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-04-21","filed_date":"2014-04-23","scope":"insider"},{"id":6294099,"accession":"0001209191-14-023549","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-14-023549","line_url":"/filing/0001209191-14-023549#line-6","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Versartis, Inc.","issuer_ticker":"VSAR","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; AISLING CAPITAL III LP; Aisling Capital Partners III LP","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":21.0,"price_display":"21.00","price_state":"stated","total_value":1260000.0,"total_display":"1,260,000.00","total_whole":"1,260,000","shares_owned_after":1994568.0,"shares_owned_after_display":"1,994,568","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-03-26","filed_date":"2014-03-27","scope":"insider"},{"id":7090754,"accession":"0000950142-14-000705","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950142-14-000705","line_url":"/filing/0000950142-14-000705#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Durata Therapeutics, Inc.","issuer_ticker":"DRTX","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Aisling Capital Partners III LLC; Aisling Capital Partners III LP; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2649.0,"shares_display":"2,649","price_per_share":15.5738,"price_display":"15.57","price_state":"stated","total_value":41254.9962,"total_display":"41,255.00","total_whole":"41,255","shares_owned_after":3030175.0,"shares_owned_after_display":"3,030,175","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-03-21","filed_date":"2014-03-21","scope":"insider"},{"id":7090752,"accession":"0000950142-14-000705","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-14-000705","line_url":"/filing/0000950142-14-000705#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Durata Therapeutics, Inc.","issuer_ticker":"DRTX","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Aisling Capital Partners III LLC; Aisling Capital Partners III LP; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":98000.0,"shares_display":"98,000","price_per_share":15.7407,"price_display":"15.74","price_state":"stated","total_value":1542588.6,"total_display":"1,542,588.60","total_whole":"1,542,589","shares_owned_after":3032824.0,"shares_owned_after_display":"3,032,824","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-03-20","filed_date":"2014-03-21","scope":"insider"},{"id":4769153,"accession":"0000950142-13-002267","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-13-002267","line_url":"/filing/0000950142-13-002267#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Zeltiq Aesthetics Inc","issuer_ticker":"ZLTQ","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Purcell Dennis J; Aisling Capital Partners III LLC; ELMS STEVE; Aisling Capital Partners III LP; AISLING CAPITAL III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":575000.0,"shares_display":"575,000","price_per_share":12.22,"price_display":"12.22","price_state":"stated","total_value":7026500.0,"total_display":"7,026,500.00","total_whole":"7,026,500","shares_owned_after":3597742.0,"shares_owned_after_display":"3,597,742","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-11-14","filed_date":"2013-11-15","scope":"insider"},{"id":3160313,"accession":"0000950142-12-001608","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950142-12-001608","line_url":"/filing/0000950142-12-001608#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Durata Therapeutics, Inc.","issuer_ticker":"DRTX","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LP; ELMS STEVE; Purcell Dennis J; SCHIFF ANDREW N; Aisling Capital Partners III LLC; AISLING CAPITAL III LP","owner_display_name":"Aisling Capital Partners III LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1111111.0,"shares_display":"1,111,111","price_per_share":9.0,"price_display":"9.00","price_state":"stated","total_value":9999999.0,"total_display":"9,999,999.00","total_whole":"9,999,999","shares_owned_after":3130824.0,"shares_owned_after_display":"3,130,824","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-07-24","filed_date":"2012-07-25","scope":"insider"},{"id":8986164,"accession":"0001181431-11-053467","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-11-053467","line_url":"/filing/0001181431-11-053467#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Zeltiq Aesthetics Inc","issuer_ticker":"ZLTQ","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; AISLING CAPITAL III LP; Aisling Capital Partners III LP; ELMS STEVE; SCHIFF ANDREW N","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":769231.0,"shares_display":"769,231","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":10000003.0,"total_display":"10,000,003.00","total_whole":"10,000,003","shares_owned_after":4172742.0,"shares_owned_after_display":"4,172,742","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-10-24","filed_date":"2011-10-25","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001581720","name":"Loxo Oncology, Inc.","url":"/issuer/0001581720","role":"Ten percent owner","n_filings":9,"first_seen":"2014-08-06","last_seen":"2018-07-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001556263","name":"Syros Pharmaceuticals, Inc.","url":"/issuer/0001556263","role":"Ten percent owner","n_filings":1,"first_seen":"2016-07-06","last_seen":"2016-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001492674","name":"T2 Biosystems, Inc.","url":"/issuer/0001492674","role":"Ten percent owner","n_filings":2,"first_seen":"2014-08-14","last_seen":"2015-12-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001513818","name":"Versartis, Inc.","url":"/issuer/0001513818","role":"Ten percent owner","n_filings":2,"first_seen":"2014-03-27","last_seen":"2015-01-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001261249","name":"AGILE THERAPEUTICS INC","url":"/issuer/0001261249","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2015-01-27","last_seen":"2015-01-27"},{"type":"issuer","type_label":"ISSUER","cik":"0000876378","name":"TRANSENTERIX INC.","url":"/issuer/0000876378","role":"Ten percent owner","n_filings":1,"first_seen":"2014-04-23","last_seen":"2014-04-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001544116","name":"Durata Therapeutics, Inc.","url":"/issuer/0001544116","role":"Ten percent owner","n_filings":2,"first_seen":"2012-07-25","last_seen":"2014-03-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001415336","name":"Zeltiq Aesthetics Inc","url":"/issuer/0001415336","role":"Ten percent owner","n_filings":2,"first_seen":"2011-10-25","last_seen":"2013-11-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001532635","retrieved_at":"2026-08-23T05:59:05+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}